Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401667 | 0.90 | NR1H2 (0.54) | NR1H2GPR119POLBMAPK1LIPG | |
| SCHEMBL4400855 | 0.88 | NR1H2 (0.52) | NR1H2GPR119POLBMAPK1NAMPT | |
| SCHEMBL2753704 | 0.82 | KDM4E (0.37) | POLB | |
| SCHEMBL4401564 | 0.81 | NR1H2 (0.52) | NR1H2GPR119POLBMAPK1LIPG | |
| SCHEMBL4401774 | 0.81 | NR1H2 (0.51) | NR1H2GPR119POLBMAPK1NAMPT | |
| SCHEMBL4401657 | 0.80 | NR1H2 (0.58) | NR1H2GPR119POLBMAPK1ESR2 | |
| SCHEMBL2753696 | 0.79 | NR1H2 (0.59) | NR1H2GPR119POLBMAPK1LIPG | |
| SCHEMBL4399121 | 0.78 | NR1H2 (0.65) | NR1H2GPR119POLBMAPK1ESR2 | |
| SCHEMBL4401692 | 0.78 | NR1H2 (0.58) | NR1H2GPR119POLBMAPK1LIPG | |
| SCHEMBL4404349 | 0.76 | NR1H2 (0.57) | NR1H2GPR119POLBMAPK1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8263598-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-11 | — | — | US | disclosed |
| US-8178535-B2 | Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8178535-B2 | Substituted sulfonamide compounds having bradykinin 1 receptor activity and use thereof as medicaments | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2009090055-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009090054-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | NR1H2 999/4885GPR119 396/4885POLB 4295/4885 |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | RPS4X, RPS4Y1, CACNA1A | NR1H2 1264/4885GPR119 1047/4885POLB 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.